Samsung BioLogics

What Samsung BioLogics does

Samsung BioLogics is a publicly listed South Korean Contract Research, Development, and Manufacturing Organization (CRDMO), trading on the Korean Stock Exchange (207940.KS) and operating as a subsidiary of Samsung Group. Founded in 2011 and headquartered in Songdo, Incheon, the company delivers end-to-end biologics services spanning cell line development, process and analytical development, formulation, drug substance manufacturing, aseptic fill-finish, bioconjugation (ADC), and mRNA services. As of FY2025, Samsung BioLogics reported record revenue of KRW 4,557 billion with Q1 2026 revenue of KRW 1,257.1 billion (+25.7% YoY) and operating profit of KRW 580.8 billion (+35% YoY), maintaining a 15-20% annual growth guidance and cumulative contract value exceeding USD 21.4 billion.

The company's core technical stack combines proprietary platforms (S-CHOice cell line with approximately 2x conventional productivity, S-DUAL bispecific antibody platform, DEVELOPICK 3.0 formulation optimization, S-HiCon high-concentration formulation, and the ExellenS manufacturing framework) with operational infrastructure totaling 845,000 liters of global capacity across Plants 1-5 in Songdo and the newly acquired Rockville, Maryland facility. In November 2025 the company spun off Samsung Bioepis to refocus as a pure-play CDMO and is now expanding via Songdo Campus 3 with a planned Plant 6, the Eli Lilly Gateway Labs Korea incubator partnership, and a CEPI pandemic preparedness alliance.

Samsung BioLogics generates revenue primarily through transaction-fee contract manufacturing services and professional services contract development, with planned additions from proprietary technology licensing. Its go-to-market is direct enterprise field sales targeting global pharmaceutical and biotech clients, supported by regional sales offices in New Jersey (2023), Tokyo (2025), and planned Amsterdam (Q3 2025), and a marketing presence at major industry events including BIO International Convention (14 consecutive years), DCAT Week, CPHI, and AACR. Customer logos include GSK, Moderna, Eli Lilly, Kineta, Enzolytics, and TaiMed Biologics, spanning both enterprise pharma and emerging biotech across oncology, infectious disease, and biosimilars.

Name

Samsung BioLogics

Legal name

Samsung Biologics Co., Ltd.

Website

https://samsungbiologics.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Samsung BioLogics is a South Korea-based CRDMO providing end-to-end biologics services from cell line development to aseptic fill-finish for global pharmaceutical and biotechnology clients, operating 845,000 liters of total manufacturing capacity across Songdo and Rockville.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Biologics contract manufacturing
• Biopharmaceutical CDMO services
• Cell line development
• Aseptic fill-finish services
• Antibody drug conjugate manufacturing

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Contract Manufacturing Services (CMO): Large-scale and small-scale manufacturing of biologics drug substance and drug product, including clinical and commercial production
2. Contract Development Services (CDO): Cell line development, process development, analytical development, and formulation services supporting clients from early development through IND filing
3. Proprietary Technology Licensing: Plans to monetize proprietary technologies including S-CHOice and S-DUAL platforms through licensing agreements as additional revenue streams

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Samsung BioLogics operates as a global Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end biologics services for pharmaceutical and biotechnology companies. The company offers integrated capabilities spanning research services (Samsung Organoids), contract development (cell line development, process and analytical development, formulation), contract manufacturing (drug substance at scales from ≤2 kL to 5-15 kL, aseptic fill-finish), advanced modalities (ADC bioconjugation, mRNA), and quality/analytical testing services.

Product overview

Samsung Biologics operates as a leading Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end biologics services. The company's integrated platform combines proprietary technology platforms (S-CHOice, S-DUAL, DEVELOPICK™ 3.0, S-HiCon™) with comprehensive service offerings spanning research (Samsung Organoids), contract development (CDO), contract manufacturing (CMO), and quality services. Services include cell line development, process and analytical development, formulation development, drug substance manufacturing, aseptic fill-finish, bioconjugation (ADC), and mRNA services. Manufacturing infrastructure includes Bio Campus I & II in Songdo, South Korea (Plants 1-5) and the Rockville Campus in Maryland, USA, providing a total capacity of 845,000 liters. The company also offers specialized platforms like ExellenS™ for standardized manufacturing operations.

Differentiator

Problem solved

Functional benefit

Brands

• Samsung Organoids: Advanced drug screening services for precision oncology using patient-derived tumor organoids
• S-HiCon™
• DEVELOPICK™
• S-CHOice
• S-DUAL
• ExellenS™

Products and services

• CRDMO Services

Quantifiable outcome

• Manufacturing capacity increased to 845,000 liters total global capacity
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered minor, flagship and core.

• TaiMed BiologicsminorStrategic or Co-development Partner · 22 June 2026Supply agreement for pharmaceutical ingredients for TMB-365, a long-acting biologic candidate currently in development. Collaboration expected to support continued development and manufacturing needs of TMB-365/380.
• Eli LillyflagshipStrategic or Co-development Partner · 22 May 2026Eli Lilly establishing Gateway Labs Korea, a biotech incubator partnership with Samsung Biologics to be built on the Songdo campus in Incheon, expected to open in 2027 as the largest Lilly base outside the United States. The facility will house up to 30 domestic biotech corporations with access to Lilly's AI platform Tune Labs and Samsung Biologics' manufacturing capabilities. Lilly announced $500 million planned investment in Korea over five years.
• C-Lab OutsidecoreStrategic or Co-development Partner · 30 April 2026Open innovation center in Songdo, Incheon set for completion July 2027 with 12,000 square meters of research and office space. First global pharmaceutical open innovation program entering Korea through a local biotech manufacturer partnership.
• CEPIcoreStrategic or Co-development Partner · 22 April 2026Strategic partnership to support global health emergency preparedness through agile manufacturing capacity and rapid response capabilities for epidemic preparedness.
• GSKflagshipOthers · 1 March 2026Samsung Biologics acquired GSK's Rockville, Maryland manufacturing facility for $353 million, marking the company's first US manufacturing presence. The deal adds 60,000 liters of drug substance capacity and retains over 500 skilled employees.
• EnzolyticscoreStrategic or Co-development Partner · 7 October 2021End-to-end CDMO services for anti-HIV and anti-SARS-CoV-2 monoclonal antibodies. Services span cell line development, clinical drug substance, and drug product manufacturing to support IND filings.
• KinetacoreStrategic or Co-development Partner · 20 July 2021End-to-end CDMO partnership for Kineta's novel anti-VISTA antibody KVA12.1 targeting solid tumors. Services include cell line development, clinical drug substance, and drug product manufacturing to support IND filing.

Scale indicators8 records

Recent moves10 records

Expansion highlights7 records

Emerging players

• Recipharm: European-based CDMO offering biologics and fill-finish services. Smaller in scale than Samsung Biologics but competes for similar biopharma clients, particularly in European markets where Samsung is establishing its Amsterdam sales presence.

Direct peers

• Lonza Group: Swiss-based CDMO and the global market leader in biologics manufacturing. Directly competes with Samsung Biologics across mammalian cell culture, mAb manufacturing, and end-to-end CDMO services for pharma and biotech clients.
• Catalent: US-based CDMO acquired by Novo Holdings, providing biologics and fill-finish services to global pharma. Direct competitor in biologics manufacturing and aseptic fill-finish, the latter being a core Samsung Biologics capability.
• AGC Biologics: Global CDMO specializing in mammalian and microbial biologics manufacturing. Directly competes with Samsung Biologics in cell line development, process development, and clinical/commercial manufacturing for biopharma clients.
• Fujifilm Diosynth Biotechnologies: Japan-based global CDMO offering biologics process development and manufacturing. Comparable in scale and service breadth to Samsung Biologics, with overlapping capabilities in mAb and recombinant protein manufacturing.
• WuXi Biologics: China-based global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing. Directly competes with Samsung Biologics, particularly on cost for mAb manufacturing; recent US BIOSECURE Act dynamics have shifted some demand toward Samsung.

Regional players

• Samsung Bioepis: Former subsidiary of Samsung Biologics (now spun off as of November 2025) focused on biosimilar development and commercialization. Highly related business with shared Samsung Group heritage and Korean operations, though now structurally separate and focused on biosimilars rather than contract services.

Broad incumbents

• Charles River Laboratories: Provides CDMO services in biologics and bioprocessing alongside its broader CRO/preclinical research offerings. Comparable end-to-end capabilities though more diversified across research models and discovery services.
• Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business and broader life sciences services, Thermo Fisher offers biologics manufacturing, fill-finish, and analytical services that overlap with Samsung Biologics' portfolio. A much larger and more diversified life sciences tools and services company.
• Boehringer Ingelheim BioXcellence: Contract biologics manufacturing arm of Boehringer Ingelheim, one of the largest pharma CDMOs globally. Overlaps with Samsung Biologics in large-scale mammalian cell culture and commercial mAb manufacturing, though operating as part of a larger pharma conglomerate.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@SamsungBiologicsofficial
• Facebookfacebook.com/samsungbiologics
• LinkedInlinkedin.com/company/samsung-biologics
• Instagraminstagram.com/samsung_biologics
• Xx.com/samsungbiologi

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Samsung BioLogics